Библиография
- Van Amsterdam PH, Overmars H, Scherpenisse
PM, et al. Dydrogesterone: metabolism in man. Eur J Drug Metab
Pharmacokin 1980; 5(3): 173-184
- Jager FC, Michielsens PMLJ, Minter, et al.
Summary of the properties of dydrogesterone. Solvay Report H.
102.053, 1988
- Sturdee DW. Hormone replacement therapy:
the benefits and risks. Prescr J 1994: 34: 234-242
- Barlow DH, Brockie JA, Rees CMP. Study of
general practice consultations and menopausal problems. Br Med
J 1991; 302: 274-276
- Lufkin EG, Wahner HW, O'FaIlon WM, et al.
Treatment of postmenopausal osteoporosis with transdermal estrogen.
Ann Int Med 1992; 117: 1-9
- Amy JJ. Femoston®: Effects on bone and quality-of-life.
Eur Menopause J 1995; 2 (4, suppl): 16-22
- Weiss NS, Ure CL, Ballard JH, et al. Decreased
risk of fractures of the hip and lower forearm with postmenopausal
use of estrogen. N Engl J Med 1980; 303: 1195-1198
- Barlow DH. Department of Health Advisory
Group on Osteoporosis Report. November 1994.
- Stampfer MJ. Colditz GA. Estrogen replacement
therapy and coronary heart disease: a quantitative assessment
of the epidemiological evidence. Prev Med 1991; 20: 47-63
- Crook D, Godsland IF. Stevenson JC. The
cardiovascular risk profile of hormone replacement therapies containing
dydrogesterone: a review. Eur Menopause J 1995; 2 (4, suppl):
23-30
- Whitehead M, Godfree V. 'Hormone replacement
therapy: Your questions answered.' London: Churchill Livingstone,
1992
- Gordon T, Kannel WB, Hjortland MC, McNamara
PM. Menopause and coronary heart disease. The Framingham study.
Ann Intern Med 1978; 89: 157-161
- Spector TD. Use of estrogen replacement
therapy in high risk groups in the United Kingdom. Br Med J 1989;
299: 1434-1435
- Sinclair KK, Bond CM, Taylor RJ. Hormone
replacement therapy; a study of women's knowledge and attitudes.
Br J Gen Pract 1993; 43:365-370
- Roberts PJ. The menopause and hormone replacement
therapy: views of women in general practice receiving hormone
replacement therapy. Br J Gen Pract 1991: 41:421-434
- Stumpf PG. Pharmacokinetics of estrogen.
Obstet Gynecol 1990;75: 9S-14S
- Coope J, Thomson JM, Poller L. Effects of
'natural estrogen' replacement therapy on menopausal symptoms
and blood clotting. Br Med J 1975; 4: 139-143
- Hunt K, Vessey M. The risks and benefits
of hormone replacement therapy. Curr Obstet Gynaecol 1991; 1:
21-27
- Wilkes HC, Meade TW. Hormone replacement
therapy in general practice: a survey of doctors in the MRC's
general practice research framework. Br Med J 1991:302:1317-1320
- Campbell S. Whitehead M. Estrogen therapy
and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4: 31-47
- Archer DF, Fischer LA, Rich D, et al. Estrace
vs Premarin for treatment of menopausal symptoms: Dosage comparison
study. Adv Therapy 1992:9: 21-31
- Daly E, Gray A, Barlow D, et al. Measuring
the impact of menopausal symptoms on quality of life. Br Med J
1993; 307: 836-840
- Quigley MET, Martin PL, Burnier AM, Brooks
P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet
Gynecol 1987;156:1516-1523
- Consensus Development Conference: diagnosis,
prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:
646-650
- Kanis JA, lohnell 0, Gullberg B, et al.
Evidence for efficacy of drugs affecting bone metabolism in preventing
hip fracture. Br Med J 1992; 305: 1124-1128
- Kiel DP, Felson DT, Anderson JJ, et al.
Hip fracture and the use of estrogens in postmenopausal women:
the Framingham study. N Engl J Med 1987; 317(19): 1169-1174
- Marx CW, Dailey GB, Cheney C, et al. Do
estrogens improve bone mineral density in osteoporotic women over
age 65? J Bone Min Res 1992; 7(11): 1275-1279
- De Cleyn K, Buytaert P, Delbeke L, Gerris
J. Equine estrogen-dydrogesterone therapy in the management of
postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1986:23:201-209
- Falkeborn M, Persson I, Terent A, Adami
HO, Lithell H, Bergstrom R. Hormone replacement therapy and the
risk of stroke. Arch Intern Med 1993; 153: 1201-1209
- Bush TL, Barrett-Connor E, Cowan LD, et
al. Cardiovascular mortality and noncontraceptive use oestrogen
in women: results from the Lipid Research Clinics Program follow-up
study. Circulation 1987,75: 1102-1109
- Stampfer MJ. Colditz GA. Estrogen replacement
therapy and coronary heart disease: a quantitative assessment
of the epidemiologic evidence. Prev Med 1991; 20: 47-63
- Henderson BE, Paganini-Hill A, Ross RK.
Estrogen replacement therapy and protection from acute myocardial
infarction. Am J Obstet Gynecol 1988: 159: 312-317
- Hunt K, Vessey M, McPherson K. Mortality
in a cohort of long-term users of hormone replacement therapy:
an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-1086
- Gambrell RD. Prevention of endometrial cancer
with progestogens. Maturitas 1986; 8: 159-168
- Burch DJ, Spowart KJM, Jesinger DK, et al.
A dose-ranging study of the use of cyclical dydrogesterone with
continuous 17b- estradiol. Br J Obstet Gynaecol 1995; 102: 243-248
- Ferenczy A, Gelfand MM. Endometrial histology
and bleeding patterns in postmenopausal women taking sequential,
combined estradiol and dydrogesterone. Obstet Gynecol (submitted)
- Van der Mooren MJ, Hanselaar AGJM, Bonn
GF, Rolland R. Changes in the withdrawal bleeding pattern and
endometrial histology during 17b-estradiol - dydrogesterone therapy
in postmenopausal women: a 2 year prospective study. Maturitas
1995; 20: 175-180
- Bergeron C. Summary of combined data on
endometrial safety considering the endpoint hyperplasia in postmenopausal
women taking sequential, combined estradiol and dydrogesterone
(Femoston). 8th Int Congr on the Menopause, Sydney, 1996 (Abstract)
- Al-Azzawi F, Habiba M. Regular bleeding
on hormone replacement therapy: a myth? Br J Obstet Gynaecol 1994;
101: 661 -662
- Gelfand M, Fugere P, Wiita B. Young H, Lorrain
J, Ferenczy A. A double-blind comparison of oral conjugated estrogens
combined with sequential dydrogesterone or medroxyprogesterone
acetate in postmenopausal women. Submitted for publication.
- Lippuner K, Hanggi W, Birkhauser MH, Jaeger
Ph. Prevention of postmenopausal osteoporosis in a comparative
study with tibolone, oral estradiol and transdermal estradiol.
1996; World Congress on Osteoporosis, Amsterdam (Abstract)
- Lees B, Pugh M, Siddle N, Stevenson JC.
Changes in bone density in women starting hormone replacement
therapy compared with those in women already established on hormone
replacement therapy Osteoporosis Int 1995; 5: 344-348
- Voetberg GA, Netelenbos JC, Kenemans P,
et al. Estrogen replacement therapy combined with four different
dosages of dydrogesterone: effect on calcium and lipid metabolism.
J Clin Endocrinol Metab 1994; 79:1465-1469
- Verhaar HJJ, Damen CA, Duursma SA, Scheven
BAA. A comparison of the action of progestins and estrogen on
the growth and differentiation of normal adult human osteoblast-like
cells in vitro. Bone 1994; 15(3): 307-311
- van Hoof HJC. van der Mooren MJ, Swinkels
LMJW, et al. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin
D: a 2-year prospective study. Calcif Tissue Int 1994; 55: 417-419
- Crook D, Stevenson IC, Siddle NC. Dydrogesterone
fails to oppose the effects of estrogen on serum lipoprotein metabolism,
7th International Congress, Menopause; 1993 Jun 20-24; Stockholm:
Abstract 260
- Ottosson UB, Johansson BG, von Schouiz B.
Subtractions of high-density lipoprotein cholesterol during estrogen
replacement therapy: a comparison between progestogens and natural
progesterone. J Obst Gynecol 1985:151: 746-750
- Gelfand M, Fugere P, Bissonnette F. Cardiovascular
risk factors during sequentially combined 17b oestradiol and dydrogesterone
(Femoston); results from a one-year study in postmenopausal women.
Submitted for publication.
- van der Mooren MJ, Demacker PNM, Thomas
CMG, et al. A 2-year study on the beneficial effects of 17b-estradiol-dydrogesterone
therapy on serum lipoproteins and Lp(a) in postmenopausal women:
no additional unfavourable effects of dydrogesterone. Eur J Obstet
Gynaecol Reprod Biol 1993:52: 117-123
- Stevenson JC, Proudler AJ, Walton C, Godsland
IF HRT mechanisms of action: carbohydrates. Int J fertil 1994;
39 (Suppl 1): 50-55
- Godsland IF, Gangar K, Walton C, et al.
Insulin resistance, secretion, and elimination in postmenopausal
women receiving oral or transdermal hormone replacement therapy.
Metabolism 1993: 42(7): 846-853
- Gaspard UJ, Wery D, Herman Ph, et al. Carbohydrate
metabolism is not impaired in postmenopausal women using micronised
estradiol and dydrogesterone for twelve months, 7th International
Congress, Menopause; 1993 Jun 20-24; Stockholm: Abstract 260
- Gaspard UJ, Gottal J-M, van den Brule FA.
Postmenopausal changes of lipid and glucose metabolism: a review
of their main aspects. Maturitas 1995; 21: 171-178
- Van der Mooren MJ, Wouters MGAJ, Blom HI,
et al. Hormone replacement therapy may reduce high serum homocysteine
in postmenopausal women. Eur J Clin Invest 1994; 24: 733-736
- Data on file, Solvay Report H102.901.MC
- Campagnoli C, Lesca L, Cantamessa C, Peris
C. Long-term hormone replacement treatment in menopause: new choices,
old apprehensions, recent findings. Maturitas 1993; 18:21-46
- Kuhl H. Pharmacokinetics of estrogens and
progestogens. Maturitas 1990; 12: 171-197
- Howell A, Bundred N, Evans G, Anderson E.
'Should I take HRT, doctor?': Hormone replacement therapy in women
at increased risk of increased breast cancer and in survivors
of the disease. J Br Men Soc 1995; 1(2):9-17
- International Medical Benefit/Risk Foundation
Workshop. Hormone replacement therapy (HRT) and breast cancer
risk. Pharmaco-epidemiol Drug Saf 1993; 2: 103-105
- Massil H, O'Brien PMS. Premenstrual syndrome.
Br Med J 1986; 293: 1289-1292
- Bancroft J, Backstrom T. Premenstrual syndrome.
Clin Endocrinol 1985; 22: 313-336
- Day JB. Clinical trials in the premenstrual
syndrome. Curr Med Res Opin 1979; 6 (Suppl. 5): 40-45
- Kerr GD, Day JB, Munday MR, et al. Dydrogesterone
in the treatment of the premenstrual syndrome. Practitioner 1980;
224: 852-855
- Haspels AA. Proceedings of a Workshop on
Premenstrual Syndrome: VIth International Congress of Psychosomatic
Obstetrics and Gynecology, Berlin, 1980: 81-92
- Smith RNJ, Studd JWW, Zamblera D. Holland
EFN. A randomised comparison over 8 months of 100mg and 200mg
twice weekly doses of transdermal estradiol in the treatment of
severe premenstrual syndrome. Br I Obst Gynaecol 1995: 102: 475-484
- Ohlenroth G, Hatzmann W. Die therapie der
juvenilen dysmenorrho mit 6-dehydro-retro-progesteron. Med Welt
1982; 33: 645-646
- West CP. Dysfunctional uterine bleeding.
Prescr J 1994; 34: 215-220
- Belaisch J. Metrorragies et desir de grossesse.
ConcMedicale 1991 (September): 880
- Eiholzer U. L'adolescente et 1'amenorrhee
secondaire. Rev Med Suisse Romande 1995; 115:609-612
- Schweppe KW. Recent Advances in the Management
of Endometriosis, ed Rock JA & Schweppe KW. Parthenon 1988: 13-30
- Johnston WIH. Dydrogesterone and endometriosis.
Br J Obstet Gynaecol 1976; 83: 77-80
- Walker SM. The treatment of endometriosis
with dydrogesterone. Br J Clin Pract 1983; Suppl. 24: 40-46
- Wiegerinck MAHM, Van Dop PA, Brosens IA.
The staging of peritoneal endometriosis by the type of active
lesion in addition to the revised American Fertility Society classification.
Fertil Steril 1993:60:461-464
- Overton CE, Lindsay PC, Johal B, et al.
A randomized, double-blind, placebo-controlled study of luteal
phase dydrogesterone (Duphaston) in women with minimal to mild
endometriosis. Fertil Steril 1994:62:701-707
- Rothe K. Gestagene und corpus-luteum-insuffizienz.
Zentralbl Gynakol 1995; 117: 2-5
- Belaisch-Allart J, Testart J, Fries N, et
al. The effect of dydrogesterone in supplementation in an IVF
programme. Human Reprod 1987; 2: 183-185
- Bishop PMF, Borell U, Diczfalusy E, Tillinger
K-G. Effect of dydrogesterone on human endometrium and ovarian
activity. Acta Endocrinol 1962; 40: 203-216
- Ullery JC, De Neef JC, Holzaepfel JH. Dydrogesterone
therapy: clinical observations and laboratory findings in 61 patients.
Obstet Gynecol 1963; 22: 38-45
- Netter A, Yaneva H, Salomon-Bernard Y. Notre
experience clinique de la dydrogesterone. Comptes Rendus Soc Fr
Gynecol1962;5:1-7
- Oddens BJ, Boulet MJ, Lehert P, Visser AP.
A study on the use of medication for climacteric complaints in
Western Europe-II. Maturitas 1994; 19: 1-12
- Crook D, Godsland IF, Hull J, Stevenson
JC. Hormone replacement therapy with dydrogesterone and 17b-oestradiol:
effects on serum lipoproteins and glucose tolerance. Submitted
for publication.
- Miller VT, Muesing RA, LaRosa JC et al.
Effects of conjugated equine estrogen with and without three different
progestogens on lipoproteins, high-density lipoprotein subfractions,
and apolipoprotein A-1. Obstet Gynecol 1991; 77(2): 235-240
|
